Clinically isolated syndrome (CIS) refers to the first clinical episode of an inflammatory demyelinating event in the central nervous system. Symptoms of CIS are similar to multiple sclerosis (MS) and includes visual disturbances, limb weakness, sensory symptoms, and impaired coordination. CIS confirms a diagnosis suggestive MS but is not diagnostic of MS. MRI scans are commonly used CIS diagnostic method and helps in planning early initiation of disease modifying treatment to prevent MS onset. The global CIS market is projected to grow rapidly owing to increasing diagnosis of CIS events, growing multiple sclerosis disease prevalence, and improved healthcare infrastructure.
The clinically isolated syndrome (CIS) market is estimated to be valued at USD 16.03 Bn in 2024 and is expected to reach USD 25.19 Bn by 2031, growing at a compound annual growth rate (CAGR) of 6.7% from 2024 to 2031.
Key Takeaways:
Key players operating in the Clinically Isolated Syndrome market are NIHON KOHDEN CORPORATION, Siemens Healthineers, Koninklijke Philips N.V., General Electric Company, Fujifilm Holdings Corporation. Growing CIS diagnosis rate supported by increased MRI usage and improving diagnostic accuracy have been the key factor boosting the market demand. Whereas, technological advancements in MRI such as artificial intelligence integrated MRI systems and portable MRI machines have improved CIS detection capabilities.
Market Trends:
Increasing Adoption of AI-Assisted Diagnosis: Integration of artificial intelligence in MRI aided image analysis has improvedautomated Clinically Isolated Syndrome Market lesion detection and characterization. This reduces diagnostic time and chances of human error.
Rise of Ambulatory Surgical Centers: Number of ambulatory surgical centers performing low risk neurology procedures including MRI scans for CIS detection has increased significantly. This improves accessibility and affordability of CIS diagnosis.
Market Opportunities:
Development of wearable CIS diagnostic devices: Ongoing research aims to develop non-invasive wearable systems like EEG, EMG patches to detect CIS related brain activity changes at early stage without need for hospital visits.
Personalized Disease Modifying Therapies: Advancements aimed at developing molecular level CIS subtype diagnosis may lead to personalized therapies tailored to individual pathology and risk of MS conversion. This could improve treatment outcomes.
How COVID-19 has impacted the Clinically Isolated Syndrome (CIS) Market growth
The COVID-19 pandemic has significantly impacted the Clinically Isolated Syndrome (CIS) Market growth globally. The pandemic restricted people's mobility and access to healthcare facilities including hospitals and clinics. This led to reduced diagnosis of CIS cases initially during the peak phase of the pandemic. Hospitals prioritized COVID-19 treatment and shifted resources including doctors, equipment and facilities towards coronavirus patients care. As a result, non-emergency treatments and procedures for other diseases like CIS faced delays.
The pandemic negatively affected the clinical trials and research activities for new CIS drugs and therapies due to lockdowns imposed worldwide. Researchers faced challenges in participant recruitment and drug administration during clinical studies. However, with relaxation in restrictions and reopening of healthcare setups post the first wave, the market is recovering gradually. The demand for CIS diagnosis and treatment is rising again with growing patient pool. Pharmaceutical companies are accelerating their efforts towards new product development and launches to cater to the increasing needs. Telehealth and digital health solutions are also helping clinicians to remotely monitor and treat CIS patients amid the ongoing pandemic.
Regional concentration in terms of value
The North America region accounts for the major share of the global Clinically Isolated Syndrome (CIS) Market in terms of value. Factors such as high prevalence of MS, stringent healthcare infrastructure, availability of advanced diagnosis and treatment options along with reimbursement policies support the market growth in the region. The increasing R&D investments by government agencies and pharma firms for new CIS drugs development further propels the regional market. Europe is the second largest market owing to rising healthcare expenditure and supportive government initiatives for rare and chronic disease management.
Fastest growing regional market
The Asia Pacific region is expected to witness the fastest growth in the Clinically Isolated Syndrome (CIS) Market over the forecast period. Rapidly developing healthcare infrastructure, improving accessibility and affordability of diagnosis and treatment drive the regional market. In addition, increasing awareness levels regarding early MS diagnosis and management aids market expansion in the Asia Pacific region. Rising medical tourism coupled with presence of less stringent regulations for clinical trials attracts pharmaceutical companies to set up manufacturing and research facilities in the emerging APAC countries. This positively influences the CIS market growth trajectory in the region.
Get More Insights - Clinically Isolated Syndrome Market
Get this Report in Japanese Language: 臨床的に孤立した症候群市場
Get this Report in Korean Language: 임상적으로 고립된 증후군 시장
Explore More Related Topics on - The Premium Sleep Experience: Exploring the World of Luxury Bedding in the UK
Author Bio:
Priya Pandey is a dynamic and passionate editor with over three years of expertise in content editing and proofreading. Holding a bachelor's degree in biotechnology, Priya has a knack for making the content engaging. Her diverse portfolio includes editing documents across different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. Priya's meticulous attention to detail and commitment to excellence make her an invaluable asset in the world of content creation and refinement.
(LinkedIn- https://www.linkedin.com/in/priya-pandey-8417a8173/)
